Epigenetic Boost Fails to Awaken Immune Therapy in Bile Duct Cancer Trial
A phase 2 trial found that the HDAC inhibitor entinostat combined with nivolumab produced no tumor responses in advanced cholangiocarcinoma, ...
A phase 2 trial found that the HDAC inhibitor entinostat combined with nivolumab produced no tumor responses in advanced cholangiocarcinoma, ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine